Mylan's (Nasdaq: MYL) generic version of Teva Pharmaceutical Industries Ltd.'s (NYSE: TEVA) Copaxone was approved by the Food and Drug Administration. Shares of Mylan leaped $5.27 to close at $37.80 while Teva Pharmaceutical stock plunged $2.74 to close at $16.08.
Mylan's generic version of Copaxone approved
October 04, 2017 at 17:12 PM EDT
